VClinbio

VClinbio is a clinical-stage biopharmaceutical company dedicated to developing innovative small molecule therapies for inflammatory diseases and cancer. The company leverages its proprietary V-Platform, which integrates medicinal chemistry and computational tools to design highly selective kinase inhibitors. Its lead candidate, VCB-102, is a dual JAK1/TYK2 inhibitor currently being evaluated for the treatment of psoriasis and other autoimmune disorders. Additionally, the company is advancing VCB-101 for myeloproliferative neoplasms and various oncology programs. VClinbio is headquartered in New Jersey and focuses on optimizing the therapeutic index of proven biological pathways. By focusing on selective inhibition, the company aims to provide safer and more effective alternatives to current standard-of-care treatments.